← Leaderboards
Ryan P Bennett
Oyagen, Inc.
$1,498,000
Attributed
$1,498,000
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $598K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,498,000 · 3
By mechanism
R43$1,498,000 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsDosePreclinical DevelopmentViralNational Institute Of Allergy And Infectious DiseaseAnimalsHalf-LifeFormulationRecommendationPreclinical StudyIn VivoSmall Business Innovation Research GrantDrug KineticsVirusAnti-Viral EfficacyChemical SynthesisClinical TrialsDrug ResistanceSerumPhase I Clinical TrialsHourAntiviral AgentsNovel TherapeuticsMedical Countermeasure
Grant awards (5)
IND-Enabling Development of a Small Molecule COVID Therapeutic$300,000
R43 · FY2024 · AI · contact PI
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly$298,000
R43 · FY2024 · AI · contact PI
IND-Enabling Development of a Small Molecule COVID Therapeutic$300,000
R43 · FY2023 · AI · contact PI
Preclinical Development of HIV Vif Antagonists$300,000
R43 · FY2019 · AI · contact PI
Preclinical Development of HIV Vif Antagonists$300,000
R43 · FY2018 · AI · contact PI